A Study to Compare the Bioequivalence of 50-mg Tapentadol (CG5503) Dose Administered as Two 25-mg Tablets Relative to One 50-mg Tablet

This study has been completed.

Sponsor:

Information provided by:

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

ClinicalTrials.gov Identifier:

NCT01273506

First received: January 7, 2011

Last updated: March 12, 2012

Last verified: March 2012

No Study Results Posted on ClinicalTrials.gov for this Study

Study Status:	This study has been completed.
Study Completion Date:	February 2011
Estimated Primary Completion Date:	No date given